Clin Exp Otorhinolaryngol.  2016 Jun;9(2):173-177. 10.21053/ceo.2015.00073.

Effect of Octreotide Injection on Postoperative Drainage After Neck Dissection: A Preliminary Report of a Prospective, Matched Case-Control Study

• Ahn D
• Jeon JH
• Kim H
• Sohn JH

• KMID: 2165062
• DOI: http://doi.org/10.21053/ceo.2015.00073

Abstract

OBJECTIVES
Somatostatin inhibits lymph production and reduces lymph flow into the lymphatic duct. We hypothesized that octreotide, a long-acting somatostatin analog, would reduce drainage after neck dissection (ND) by reducing the overall lymphatic flow in the neck as well as thoracic duct flow.
METHODS
From 2012 to 2014, total 123 patients who had undergone left-sided comprehensive ND, were divided into an octreotide group (49 patients) and a control group (74 patients). Seventeen patients from the octreotide group and 17 from the control group were individually matched by age (±10 years), sex, body mass index (±1 kg/m2), type of cancer, surgeon, and the extent of surgery. These 34 patients were finally included in the study.
RESULTS
The total fluid drainage volume (540.9 mL vs. 707.9 mL) and drainage volume during the period of octreotide use (the first 5 postoperative days) (461.1 mL vs. 676.4 mL) were significantly lower in the octreotide group. The duration of drain placement (6.3 days vs. 9.4 days) was also shorter in the octreotide group. In the octreotide group, the mean triglyceride concentration in the drainage fluid was significantly lower than that in the control group (43.1 mg/dL vs. 88.8 mg/dL). There was no complication associated with the use of octreotide.
CONCLUSION
Our study has shown that postoperative octreotide injections reduce postoperative drainage and the duration of drain placement. Further studies with larger patient populations are warranted to confirm these results and to evaluate the clinical benefits for patients.

Keyword

Chyle; Drainage; Neck Dissection; Somatostatin; Triglyceride

MeSH Terms

Body Mass Index
Case-Control Studies*
Chyle
Drainage*
Humans
Neck Dissection*
Neck*
Octreotide*
Prospective Studies*
Somatostatin
Thoracic Duct
Triglycerides
Octreotide
Somatostatin

Reference

1. Givi B, Linkov G, Ganly I, Patel SG, Wong RJ, Singh B, et al. Selective neck dissection in node-positive squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg. 2012; Oct. 147(4):707–15.

2. Strong EW. Preoperative radiation and radical neck dissection. Surg Clin North Am. 1969; Apr. 49(2):271–6.

3. Byers RM, Ballantyne AJ, Goepfert H, Guillamondegui OM, Larson DL, Medina J. Clinical effects of closed suction drainage on wound healing in patients with head and neck cancer. Arch Otolaryngol. 1982; Nov. 108(11):723–6.

4. Durai R, Mownah A, Ng PC. Use of drains in surgery: a review. J Perioper Pract. 2009; Jun. 19(6):180–6.

5. Spotnitz WD. Fibrin sealant: past, present, and future: a brief review. World J Surg. 2010; Apr. 34(4):632–4.

6. Ochiai T, Sonoyama T, Soga K, Inoue K, Ikoma H, Shiozaki A, et al. Application of polyethylene glycolic acid felt with fibrin sealant to prevent postoperative pancreatic fistula in pancreatic surgery. J Gastrointest Surg. 2010; May. 14(5):884–90.

7. Di Monta G, Caraco C, Crispo A, Marone U, Mozzillo N. Collagen sealant patch to reduce lymphatic drainage after lymph node dissection. World J Surg Oncol. 2012; Dec. 10:275.

8. Vida VL, Padalino MA, Barzon E, Stellin G. Efficacy of fibrinogen/thrombin-coated equine collagen patch in controlling lymphatic leaks. J Card Surg. 2012; Jul. 27(4):441–2.

9. Figueras J, Llado L, Miro M, Ramos E, Torras J, Fabregat J, et al. Application of fibrin glue sealant after hepatectomy does not seem justified: results of a randomized study in 300 patients. Ann Surg. 2007; Apr. 245(4):536–42.

10. Lee MG, Jones D. Applications of fibrin sealant in surgery. Surg Innov. 2005; Sep. 12(3):203–13.

11. Swan MC, Oliver DW, Cassell OC, Coleman DJ, Williams N, Morritt DG, et al. Randomized controlled trial of fibrin sealant to reduce postoperative drainage following elective lymph node dissection. Br J Surg. 2011; Jul. 98(7):918–24.

12. Ulibarri JI, Sanz Y, Fuentes C, Mancha A, Aramendia M, Sanchez S. Reduction of lymphorrhagia from ruptured thoracic duct by somatostatin. Lancet. 1990; Jul. 336(8709):258.

13. Nussenbaum B, Liu JH, Sinard RJ. Systematic management of chyle fistula: the Southwestern experience and review of the literature. Otolaryngol Head Neck Surg. 2000; Jan. 122(1):31–8.

14. Valentine CN, Barresi R, Prinz RA. Somatostatin analog treatment of a cervical thoracic duct fistula. Head Neck. 2002; Aug. 24(8):810–3.

15. Szabados E, Toth K, Mezosi E. Use of octreotide in the treatment of chylopericardium. Heart Lung. 2011; Nov-Dec. 40(6):574–5.

16. Coskun A, Yildirim M. Somatostatin in medical management of chyle fistula after neck dissection for papillary thyroid carcinoma. Am J Otolaryngol. 2010; Sep-Oct. 31(5):395–6.

17. Roh JL, Kim DH, Park CI. Prospective identification of chyle leakage in patients undergoing lateral neck dissection for metastatic thyroid cancer. Ann Surg Oncol. 2008; Feb. 15(2):424–9.

18. Nakabayashi H, Sagara H, Usukura N, Yoshimitsu K, Imamura T, Seta T, et al. Effect of somatostatin on the flow rate and triglyceride levels of thoracic duct lymph in normal and vagotomized dogs. Diabetes. 1981; May. 30(5):440–5.

19. Gregor RT. Management of chyle fistulization in association with neck dissection. Otolaryngol Head Neck Surg. 2000; Mar. 122(3):434–9.

20. Woodworth PA, McBoyle MF, Helmer SD, Beamer RL. Seroma formation after breast cancer surgery: incidence and predicting factors. Am Surg. 2000; May. 66(5):444–50.